Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chronic myelogenous leukemia in chronic phase.

R Kurzrock1, H Kantarjian, M Talpaz

  • 1Department of Bioimmunotherapy, Box 422, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

Current Treatment Options in Oncology
|June 12, 2002
PubMed
Summary

STI571 shows promise in revolutionizing Chronic Myelogenous Leukemia (CML) treatment, offering high remission rates with low toxicity. Further research is needed to optimize its use as a front-line therapy for CML patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term outcomes of Sleeping Beauty-generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas.

Blood·2020
Same author

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML.

Blood·2020
Same author

Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse.

Leukemia·2017
Same author

Influence of IDH on FLT3-ITD status in newly diagnosed AML.

Leukemia·2017
Same author

Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy.

Leukemia·2017
Same author

Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL).

Annals of oncology : official journal of the European Society for Medical Oncology·2017

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Chronic myelogenous leukemia (CML) is a myeloproliferative disorder with inevitable progression.
  • The BCR-ABL molecular abnormality drives CML pathogenesis.
  • Targeted therapies are crucial for managing CML evolution.

Purpose of the Study:

  • To evaluate the efficacy and safety of STI571 in CML treatment.
  • To assess STI571's potential as a front-line therapy for CML.
  • To identify key areas for future clinical research in CML management.

Main Methods:

  • Clinical trials of STI571 in patients with CML.
  • Analysis of hematologic and cytogenetic remission rates.
  • Assessment of treatment toxicity and side effect profiles.

Related Experiment Videos

Main Results:

  • STI571 demonstrated significant hematologic and cytogenetic remission rates in advanced CML.
  • Early clinical trials showed responses even in blast crisis.
  • STI571 exhibited a favorable toxicity profile.

Conclusions:

  • STI571 is poised to revolutionize CML treatment, becoming a front-line therapy.
  • Further clinical studies are essential to resolve issues regarding molecular remission, resistance, treatment duration, and survival impact.
  • Combination therapy with interferon-alfa and allogeneic hematopoietic cell transplant are potential strategies for managing resistant or advanced CML.